ClinicalTrials.gg
Enrolling by invitationNCT06931132FORESTUpdated Sep 22, 2025

Cancer-related Fatigue and Symptom Clusters - Effects of Virtual, Imagined and Real-life Nature-based Therapy in Cancer Survivors

An interventional study of Real-life forest bathing and Simulated FOREST bathing (Virtual Reality) in Cancer Survivors, sponsored by Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF). Enrolling by invitation at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Fatigue with a site in Germany — 20 open to participants now, 25 under way, 3 of them phase 3. Fatigue · Germany.

Planned enrollment
14th of 50
172 · median 90
Started
2025
with 3 others
No phase
32 of 62
11 open now
Primary completion
2027-07
later than 14 of 24 live
Registered
50th of 62
by date

Among the 62 studies in Fatigue with a site in Germany, this one is the 14th largest by planned enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2025, is one of 32 with no phase, reaches primary completion later than 14 of the 24 other live ones, and was the 50th registered.

Fatigue

2,234 studies on the registry are indexed under Fatigue; 430 are open to participants now.

Browse Fatigue studies →

Open to participants now

20 of the 62 studies in Fatigue with a site in Germany are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 242 Fatigue studies recruiting now, 113 (47%) set no upper age limit and 99 (41%) stop at 75 or younger; 23 take children under 18; 74 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Fatigue with a site in Germany, or all of them as a file.
02

Study summary

This is a randomized, controlled, bicenter trial comparing the effects on symptoms and quality of life in cancer survivors. Three nature-based therapies will be compared with a wait-list group. The therapies are: virtual reality simulated forest, guided imaging and classic forest bathing. Each intervention lasts 30 minutes and takes place once a week for 8 weeks. All interventions involve different stimulus types: visual, olfactory, auditory and tactile.

03

Conditions studied

  • Cancer Survivors

Browse trials for

Keywords

  • Fatigue
  • Forest therapie
  • Virtual Reality
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have completed treatment for cancer (*with the exception of long-term endocrine therapy).
  • Subjective Impairment due to Cancer-Related Fatigue (CrF) . NCCN-recommended questions are used for screening ("How exhausted do you feel on a scale of 0 to 10?" and "How impaired do you feel by this fatigue on a scale of 0 to 10?" (threshold >4 on either scale).
  • At the time of study inclusion, it must be expected that no further antitumor therapy measures will be started within the next 6 months.
  • Patients must be able to refrain from smoking up to 15 minutes before the intervention (smoking within 15 minutes before therapy impairs the participant's ability to perceive the aroma of the phytoncides).
  • Written and valid from the patient.

Exclusion criteria

Exclusion Criteria:

  • Presence of inadequately controlled major depression in the opinion of the investigator.
  • Asthma (inhaled phytoncides may cause airway irritation, exacerbation of asthma, or bronchoconstriction).
  • Known allergy to pine or citrus fragrance.
  • Anosmie.
  • Medical history of seasickness (virtual reality can cause nausea/vomiting with no improvement after 5-10 minutes).
  • History of seizures (virtual reality may increase susceptibility to seizures due to the changing light in the forest video).
  • Visual and hearing impairments that are not corrected by visual or hearing aids.
  • Unwillingness to store and share personal medical data as part of the protocol.
  • Participation in another clinical trial focusing on behavioural or complementary medicine interventions.
  • Missing or incomplete consent form.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
172 participants (estimated)

Study arms

  • Experimental
    Real-life FOREST bathing

    Other: Real-life forest bathing

  • Experimental
    Simulated FOREST bathing (Virtual Reality).

    Other: Simulated FOREST bathing (Virtual Reality)

  • Experimental
    Imaging FOREST bathing.

    Other: Imaging FOREST bathing

  • No intervention
    Wait-list group

Interventions

  • OtherReal-life forest bathing

    Participants will experience the elements (olfactory, acoustic and haptic) of forest bathing for 30 minutes (sitting) in a forested area. The forests have been previously selected near Stuttgart and Würzburg and are comparable to each other.

  • OtherSimulated FOREST bathing (Virtual Reality)

    Using virtual reality goggles, a FOREST bathing experience will be simulated. The simulation will have elements of the classic FOREST bathing (olfatory, acoustic and haptic) and will last 30 minutes.

  • OtherImaging FOREST bathing

    A therapist will lead an imaginative exercise in which participants will imagine a FOREST bathing. The imaginative exercise will include elements of the classic FOREST bathing (olfactory, acoustic and haptic) and will last 30 minutes.

06

What researchers measure

Primary outcomes

  1. Fatigue

    The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) is a validated tool for the reliable measurement of fatigue in patients with cancer and other chronic diseases. The questionnaire has high internal consistency and validity and allows assessment of fatigue and its impact on quality of life and disease progression. 13 items to measure self-reported fatigue and its impact on daily activities and functions. Scores range from 0 to 52, with higher scores indicating less fatigue (better outcome).

    Time frame: 8 weeks (end of intervention)

  2. Sleep

    The Pittsburgh Sleep Quality Index (PSQI) measures subjective sleep quality. The 19-item questionnaire generates seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime disturbances. The sum of the scores for these seven components gives a global score. Scores range from 0 to 21, with higher scores indicating poorer sleep quality (worse outcome).

    Time frame: 8 weeks (end of intervention)

  3. Depression

    The Patient Health Questionnaire-9 (PHQ-9) is often used for the initial diagnosis of depression and for monitoring the course of the illness. The PHQ-9 consists of 9 questions that ask about the main and core symptoms of depression over the past two weeks, providing a structured and objective assessment of the severity of depression. Scores range from 0 to 27, with higher scores indicating more severe depression (worse outcome).

    Time frame: 8 weeks (end of intervention)

  4. Concentration

    The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) is a 5-point Likert scale measure of chemotherapy-induced cognitive impairment in cancer patients. The questionnaire consists of 24 items covering four different domains: self-perceived cognitive impairment, feedback from others, perceived cognitive ability, and impact on quality of life. The assessment of these cognitive aspects indicates a relationship with objective symptoms and allows for a nuanced assessment of treatment-induced cognitive impairment. Scores range from 0 to 148, with higher scores indicating better perceived cognitive functioning (better outcome).

    Time frame: 8 weeks (end of intervention)

Secondary outcomes

  1. Fatigue

    The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) is a validated tool for the reliable measurement of fatigue in patients with cancer and other chronic diseases. The questionnaire has high internal consistency and validity and allows assessment of fatigue and its impact on quality of life and disease progression. 13 items to measure self-reported fatigue and its impact on daily activities and functions. In addition to the primary outcome (overall fatigue score), this secondary outcome will focus on specific FACIT-F items related to fatigue interference in daily activities. This aims to explore functional limitations due to fatigue beyond the global score. Scores range from 0 to 52, with higher scores indicating less fatigue (better outcome).

    Time frame: 8 weeks (end of intervention)

  2. Sleep

    The Pittsburgh Sleep Quality Index (PSQI) measures subjective sleep quality. The 19-item questionnaire generates seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime disturbances. The sum of the scores for these seven components gives a global score. Scores range from 0 to 21, with higher scores indicating worse sleep quality (worse outcome).

    Time frame: 8 weeks (end of intervention)

  3. Depression

    The Patient Health Questionnaire-9 (PHQ-9) is often used for the initial diagnosis of depression and for monitoring the course of the illness. The PHQ-9 consists of 9 questions that ask about the main and core symptoms of depression over the past two weeks, providing a structured and objective assessment of the severity of depression. Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms (worse outcome).

    Time frame: 8 weeks (end of intervention)

  4. Concentration

    The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) is a 5-point Likert scale measure of chemotherapy-induced cognitive impairment in cancer patients. The questionnaire consists of 24 items covering four different domains: self-perceived cognitive impairment, feedback from others, perceived cognitive ability, and impact on quality of life. The assessment of these cognitive aspects indicates a relationship with objective symptoms and allows for a nuanced assessment of treatment-induced cognitive impairment. Scores range from 0 to 148, with higher scores indicating better cognitive function (better outcome).

    Time frame: 8 weeks (End of intervention)

  5. Resilience

    The Brief Resilience Scale (BRS) is a instrument used to measure resilience, or an individual's ability to bounce back quickly from stress, adversity, or challenge. The BRS is known for its brevity and conciseness, with only a few items rated on a Likert scale. Scores range from 1 to 5, with higher scores indicating greater resilience (better outcome).

    Time frame: 8 weeks (end of intervention)

  6. Mindfulness

    The Mindfulness Awareness Scale (MAAS) measures a person's level of mindfulness. The scale ranges from 1 to 6 and includes a total of 15 items. The items assess the extent to which a person invests his or her thoughts in the present moment by taking into account the extent to which he or she is aware of what is going on in his or her environment at any given moment. Scores range from 15 to 90, with higher scores indicating greater mindfulness (better outcome).

    Time frame: 8 weeks (end of intervention)

  7. Anxiety

    The Generalized Anxiety Disorder-7 (GAD-7) is a standardized screening questionnaire used to assess the severity of generalized anxiety disorder. It is used in both clinical practice and research to rapidly identify and assess the severity of anxiety symptoms. The questionnaire consists of 7 items that ask about typical symptoms of generalized anxiety disorder and focus on the last two weeks. Scores range from 0 to 21, with higher scores indicating more severe anxiety (worse outcome)

    Time frame: 8 weeks (end of intervention)

  8. Quality of life Questionnaire

    Functional Assessment of Cancer Therapy - (FACT-G) Quality of Life Questionnaire. The FACT-G was developed through a structured process to identify relevant content for a cancer-specific quality of life questionnaire. The instrument allows the calculation of a generic total quality of life scale (FACT-G) as well as subscales for physical, social, emotional, and functional quality of life. Scores range from 0 to 108, with higher scores indicating better quality of life (better outcome).

    Time frame: 8 weeks (end of intervention)

  9. Sensation of stress

    The Perceived Stress Scale (PSS) is the most frequently used psychological instrument for measuring the perception of stress. It measures the degree to which situations in a person's life are perceived as stressful. The scale also includes a series of direct questions about the current experience of stress. The items are easy to understand and the response alternatives are easy to record. The questionnaire consists of 10 items. Scores range from 0 to 40, with higher scores indicating greater perceived stress (worse outcome).

    Time frame: 8 weeks (end of intervention)

  10. Simulator Disease (Virtual reality group only, arm 2)

    The Simulator Sickness Questionnaire (SSQ) is a standardised instrument designed to assess symptoms of simulator or motion sickness commonly experienced when using virtual reality (VR) and other simulated environments. The instrument consists of a series of questions divided into three subscales: Nausea, Disorientation and Oculomotor Stress. The SSQ is widely used in VR research as it provides a means of quantifying symptoms and assessing their severity. Studies have shown that the SSQ is valid and reliable and has a high correlation with actual experienced symptoms. The results of the SSQ can be used to optimise VR experiences and improve usability. Total scores range from 0 to 235.62, with higher scores indicating greater simulator sickness (worse outcome).

    Time frame: 8 weeks (end of intervention)

  11. Physical Activity and Sport Questionnaire

    Physical activity will be assessed using the Physical Activity and Sport Questionnaire (BSA), which records the frequency and type of physical activity in the past 4 weeks. Scores will be calculated in MET-minutes/week, based on self-reported duration and intensity of different physical activity domains (work, leisure, sport). Higher scores indicate higher levels of physical activity (better outcome).

    Time frame: 8 weeks (end of intervention)

  12. Safety evaluation

    To assess safety, participants will be asked whether they experienced any adverse events (AEs) during the 8-week intervention period. All reported AEs will be documented and classified by type and severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The outcome will be the number of participants with at least one treatment-related adverse event recorded from baseline through the end of the 8-week intervention.

    Time frame: Through 8 weeks of intervention (Weeks 0-8)

  13. Average daily step count (measured via wearable activity tracker)

    Physical activity will be monitored continuously during the 8-week intervention using a commercially available wearable device (e.g., Fitbit or Garmin). The tracker will record daily step counts, active minutes and movement intensity. The outcome will be the average number of steps per day during Week 8, as a marker of overall movement behavior. This complements patient-reported activity recorded in the physical activity diary.

    Time frame: Cumulative average daily steps over Weeks 1-8

  14. Heart rate variability

    Heart Rate Variability (HRV) is measured to assess autonomic nervous system activity and stress recovery. HRV will be recorded using a wearable chest strap sensor (e.g., Polar H10) or equivalent device, over a 5-minute resting period. Outcome will be RMSSD (Root Mean Square of Successive Differences) in milliseconds.

    Time frame: 8 weeks (end of intervention)

  15. Natural killer cell activity

    Natural killer (NK) cell activity will be assessed by blood sampling at baseline and Week 8. Cytotoxic activity will be measured by flow cytometry based on CD107a expression and IFN-gamma production. Outcome will be the percentage of NK cells expressing CD107a after stimulation.

    Time frame: 8 weeks (end of intervention)

  16. Serum cytokine concentrations (IL-6, IL-10, TNF-alpha)

    Serum cytokines (IL-6, IL-10, TNF-alpha) will be measured using multiplex ELISA from venous blood samples collected at baseline, Week 4 and Week 8. Outcomes will be reported as individual changes in cytokine concentrations (pg/mL) from baseline to Week 4 and Week 8.Outcomes will be reported as individual changes in cytokine concentrations (pg/mL); no composite score will be calculated.

    Time frame: Week 4 (Mid-intervention), Week 8 (End of intervention)

07

Study locations

2 sites
  • Dr med. Marcela Winkler
    Stuttgart, Baden-Wurttemberg 70439, Germany
  • PD Dr. Claudia Löffler
    Würzburg, Bavaria 97080, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2027, 25 months after the start.

Of 937 non-industry interventional studies with no phase under Fatigue, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 25 months is above that.

Counting every sponsor, half of 990 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 17, 2025
StartActual
Jun 5, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06931132
Lead sponsor
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Collaborators
Wuerzburg University Hospital, University Hospital Tuebingen
Responsible party
Marcela Winkler, MD (Head of Integrative Medicine, Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)) — Principal investigator
First posted
Apr 17, 2025
Start date
Jun 5, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 22, 2025

Study contacts

Claudia Loeffler, Dr.
principal investigator · Würzburg University. Würzburg, Bayern, Germany, 97080
Marcela Winkler, Dr.
principal investigator · Robert-Bosch-Krankenhaus, Stuttgart, Baden Würtemberg, Germany, 70341

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion